

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(formerly known as ASIA PACIFIC SILK ROAD INVESTMENT COMPANY LIMITED 亞太絲路投資有限公司)

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that on 11 June 2021, the Company entered into a memorandum of understanding (the “**MOU**”) with Ortho Clinical Diagnostics Holdings plc (“**Ortho**”) in relation to the formation of a strategic partnership between the parties. The parties shall cooperate on the evaluation of the analysis of biomarker products used for longevity and health research in medical diagnostic laboratories.

TERM OF COOPERATION

Unless terminated by written agreement between both parties, the cooperation shall be effective from the date of the execution thereof for a term of three (3) years. The final agreement shall take effect upon the execution thereof. Ortho shall be entitled to, for the sake of convenience, terminate the final agreement without liability by notice to the Company less than six (6) months in advance.

INFORMATION ON ORTHO

Ortho is a leading global provider of in vitro diagnostics and provides services to the global clinical laboratory and immunohematology communities. It has a global workforce of more than 4,500 and is headquartered in Raritan, New Jersey, the United States of America. The trading of the ordinary shares of Ortho began on The Nasdaq Global Select Market on 28 January 2021, under the symbol “OCDX”.

REASONS FOR AND BENEFITS OF THE MOU

The Board believes that the formation of the strategic partnership will further refine the global layout of the Group’s longevity science business and strengthen the leading position of the Group in longevity medical examination, thereby bringing stable and sustainable revenue growth to the Group in the long run.

The MOU does not constitute a binding commitment, or an offer to enter into a binding commitment. Shareholders and potential investors of the Company should note that the formation of the strategic partnership may or may not proceed. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 11 June 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)

Mr. Wang Hongxin (*Chief Executive Officer*)

Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon

Ms. Wang Weixia

Mr. Chai Nan

Non-executive Director

Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.